Longevity biotech founders stories

Jul 14, 2026

Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline

An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.

Jul 14, 20268 sources

Longevity biotech founders stories

Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline

ALZpath Signs Global Licensing Agreement with Abbott Laboratories for Alzheimer's Blood Test Development

First human receives cellular reprogramming therapy in landmark anti-aging clinical trial

NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine

Longevity Startup Retro Biosciences Raises Funding at $1.8 Billion Valuation

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Google's Isomorphic Labs Raises Over $2 Billion for AI Drug Discovery

BioAge Labs Reports Experimental Cardiovascular Drug Significantly Reduced Inflammation in Early Study

Biotech Venture Capital Model Faces Disruption as Traditional Formula Under Pressure

Gilead Acquires German Cancer Biotech Tubulis for Over $3 Billion

FDA Delay Forces Small Biotech Company to Shut Down Operations

Abu Dhabi Stem Cells Center Develops Technique to Generate Brain Stem Cells from Patient's Own Cells

Small Molecule Drug Candidate Shows Promise for Rare Kidney Stone Disease with No Current Treatment

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration